October 2023: The Patent for InstaVitria^® Technology Was Granted in Both India and China

 

With the support of the NIH SBIR Phase II Award from NIH ORIP, CryoCrate LLC nationalized the PCT filing of the InstaVitria^® technology in multiple countries or regions in 2020. The goal was to secure the IP protection in the global market for tissue engineering and transplantation, which was dominated by USA, China, EU, Japan, and India. In 2023, both China and India granted the patent. While waiting for the decision from other countries, CryoCrate is now working with industrial partners to establish GMP production and biocompatibility qualification and secure FDA approval for cryopreservation of transplantable tissues.